Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2No longer available 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Lymphoid 69Other hematologic neoplasm 50CNS 35Thoracic 29Breast 24Plasma cell 21Dermatologic 20Gastrointestinal 19Myeloid 17Genitourinary 17Sarcoma 16Other solid neoplasm 10Head & Neck 10Gynecologic 9Classical hematology 7Tumor-Agnostic 4Endocrine 3

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroblastoma 1Medulloblastoma 1Familial ependymoma 1Choroid Plexus Neoplasms 1Carcinoma, Medullary 1Astrocytoma 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Vorinostat × Endocrine × Clear all
NCT01838187 2023-08-18

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Children's Hospital Medical Center, Cincinnati

No longer available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT00134043 2014-08-11

Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 11 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

NCT01076530 2013-05-03

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSEndocrine

Familial ependymoma, Astrocytoma, Medulloblastoma, Oligodendroglioma, Paraganglioma, Extra-Adrenal, Spinal Cord Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡